New therapeutic strategies for the treatment of acute lymphoblastic leukaemia

[1]  H. Kantarjian,et al.  Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. , 2007, Blood.

[2]  D. Neuberg,et al.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.

[3]  D. Bergstrom,et al.  MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. , 2007, Blood.

[4]  Susan O'Brien,et al.  Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. , 2007, Blood.

[5]  M. Andreeff,et al.  Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). , 2006 .

[6]  F. Behm,et al.  Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. , 2006, Blood.

[7]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[8]  G. Garcia-Manero,et al.  Activity of alemtuzumab in patients with CD52‐positive acute leukemia , 2006, Cancer.

[9]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[10]  D. Hicklin,et al.  IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. , 2006, Cancer Research.

[11]  Sachin R. Shah,et al.  Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy , 2006, Pharmacotherapy.

[12]  R. Arceci,et al.  Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[14]  M. Andreeff,et al.  Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C , 2006, Leukemia.

[15]  R. Dillman.  Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies , 2006, Clinical and Experimental Medicine.

[16]  H. Dombret,et al.  High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia , 2006, Leukemia.

[17]  E. Giné,et al.  ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia , 2006, Clinical Cancer Research.

[18]  D. Teachey,et al.  The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. , 2006, Blood.

[19]  S. Armstrong,et al.  Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia , 2006, Leukemia.

[20]  J. Teruya-Feldstein,et al.  The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma , 2006, Clinical Cancer Research.

[21]  William E. Evans,et al.  Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy , 2006, Nature Reviews Cancer.

[22]  G. Daley,et al.  Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy , 2006, Cancer.

[23]  J. Walling.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates , 2006, Investigational new drugs.

[24]  S. Grant,et al.  RETRACTION: Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells That Overexpress Bcl-2 , 2006, Molecular Pharmacology.

[25]  H. Kantarjian,et al.  A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). , 2005, Blood.

[26]  A. Passaniti,et al.  Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias , 2005, Clinical Cancer Research.

[27]  D. Fabbro,et al.  FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model , 2005, Oncogene.

[28]  H. Ishii,et al.  Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib , 2005, Acta Haematologica.

[29]  C. Bloomfield,et al.  Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102). , 2005 .

[30]  A. Zelenetz,et al.  Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity. , 2005 .

[31]  R. Fanin,et al.  Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma. , 2005 .

[32]  T. Albertson,et al.  Intensive Care Unit Admissions in Patients with Hematologic Malignancies: Outcomes and Prognostic Indicators. , 2005 .

[33]  P. Hadwiger,et al.  Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. , 2005, Blood.

[34]  J. Verweij,et al.  Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  N. A. Libri,et al.  Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. , 2005, Blood reviews.

[36]  Assam El-Osta,et al.  RNA interference and potential therapeutic applications of short interfering RNAs , 2005, Cancer Gene Therapy.

[37]  W. McBride,et al.  Anthracyclines, proteasome activity and multi-drug-resistance , 2005, BMC cancer.

[38]  S. Armstrong,et al.  Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  V. Poggi,et al.  Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. , 2005, Blood.

[40]  W. Hiddemann,et al.  Global approach to the diagnosis of leukemia using gene expression profiling. , 2005, Blood.

[41]  I. Bernstein,et al.  Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. , 2005, Blood.

[42]  J. Leonard,et al.  Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Raimondi,et al.  Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes , 2005, Nature Genetics.

[44]  G. Ledderose,et al.  Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines , 2005 .

[45]  L. Stenberg,et al.  Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab , 2005, Clinical Cancer Research.

[46]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[47]  R. Foà,et al.  FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia , 2005, British journal of haematology.

[48]  R. Mesa,et al.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. , 2005, Blood.

[49]  G. Rosner,et al.  Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[51]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[52]  J. Kurtzberg,et al.  Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Kurtzberg,et al.  Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  D. Vallera,et al.  A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma , 2005, Clinical Cancer Research.

[55]  Yoo-Jin Kim,et al.  The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2005, Blood.

[56]  A. Narendran,et al.  Effects of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Bcr-Abl Status and Imatinib Mesylate Sensitivity , 2005, Pediatric Research.

[57]  J. Bae,et al.  Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies , 2005, Clinical Cancer Research.

[58]  Srinivas Annavarapu,et al.  Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. , 2005, Blood.

[59]  R. Giavazzi,et al.  Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo , 2005, British journal of haematology.

[60]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[61]  Dario Campana,et al.  FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. , 2005, Blood.

[62]  M. Offidani,et al.  Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL) , 2005, Leukemia & lymphoma.

[63]  T. Naoe,et al.  Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. , 2004, Blood.

[64]  S. Inoue,et al.  Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies , 2004, Cell Death and Differentiation.

[65]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[66]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[67]  E. Cook,et al.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. , 2004, Blood.

[68]  M. Offidani,et al.  Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL). , 2004 .

[69]  M. Bernstein,et al.  Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. , 2004, Blood.

[70]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[71]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[72]  A. Ferrando,et al.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia , 2004, Nature Genetics.

[73]  F. Mandelli,et al.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.

[74]  N. Winick,et al.  Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  S. Grant,et al.  Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation , 2004, Leukemia.

[76]  L. Fouillard,et al.  Remission of adult acute lymphocytic leukaemia with Alemtuzumab , 2004, Leukemia.

[77]  J. Leonard,et al.  Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[78]  B. Smith,et al.  In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. , 2004, Blood.

[79]  M. Hudson,et al.  Long‐term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk‐based Health Care for Survivors , 2004, CA: a cancer journal for clinicians.

[80]  Steven M Kornblau,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[81]  M. Relling,et al.  Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia , 2004, Leukemia.

[82]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[83]  A. Scuto,et al.  Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 , 2004, Cancer Research.

[84]  G. Fey,et al.  Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. , 2004, Blood.

[85]  E. Estey,et al.  Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias , 2004, Clinical Cancer Research.

[86]  W. Jędrzejczak,et al.  Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study , 2004, Leukemia.

[87]  D. Goldenberg,et al.  Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[88]  M. Baccarani,et al.  Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation , 2004, Leukemia & lymphoma.

[89]  E. Estey,et al.  Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Luoping Zhang,et al.  Hypermethylation of the 5′ CpG Island of the FHIT Gene Is Associated with Hyperdiploid and Translocation-Negative Subtypes of Pediatric Leukemia , 2004, Cancer Research.

[91]  H. Kantarjian,et al.  Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. , 2004, Blood.

[92]  J. Falkenburg,et al.  Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity , 2004, Leukemia.

[93]  A. Balduzzi,et al.  Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation , 2003, Leukemia.

[94]  H. Kantarjian,et al.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.

[95]  T. Tauchi,et al.  BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[96]  J. Gill,et al.  Thymic generation and regeneration , 2003, Immunological reviews.

[97]  M. Relling,et al.  Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. , 2003, The New England journal of medicine.

[98]  A. O'marcaigh,et al.  Successful use of gemtuzumab ozogamicin in a child with relapsed cd33‐positive acute lymphoblastic leukaemia , 2003, British journal of haematology.

[99]  K. Bhalla,et al.  Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. , 2003, Blood.

[100]  F. Khuri,et al.  Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  D. Reinhardt,et al.  Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin , 2003, Leukemia.

[102]  M. Grever,et al.  Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells , 2003, Leukemia.

[103]  Rob Pieters,et al.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. , 2003, Cancer cell.

[104]  M. Caligiuri,et al.  Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. , 2003, Blood.

[105]  A. Zelenetz,et al.  Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression , 2003, Leukemia & lymphoma.

[106]  M. Diccianni,et al.  The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. , 2002, Blood.

[107]  Gabriela Chiosis,et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. , 2002, Blood.

[108]  D. Isenberg,et al.  An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[109]  P. Dent,et al.  Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[110]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[111]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[112]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[113]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[114]  T. Ahmed,et al.  Phase I study of temozolomide in relapsed/refractory acute leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  G. Daley,et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. , 2002, Blood.

[116]  P. Mclaughlin,et al.  Trimetrexate in relapsed T-cell lymphoma with skin involvement. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  A. Ganser,et al.  Tumor suppressor genes in normal and malignant hematopoiesis , 2002, Oncogene.

[118]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[119]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[120]  E. Lander,et al.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.

[121]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[122]  A. Nudelman,et al.  Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). , 2001, Cancer research.

[123]  D. Campana,et al.  Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.

[124]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[125]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[127]  J. Montgomery,et al.  Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent. , 2001, International immunopharmacology.

[128]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[129]  B. Pollock,et al.  Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study , 2000 .

[130]  T. Lebien,et al.  Fates of human B-cell precursors. , 2000, Blood.

[131]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  S. Phuphanich,et al.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  A. Hall,et al.  Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. , 1999, Blood.

[134]  K. Gelmon,et al.  Phase I study of liposomal vincristine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  J. Radich,et al.  The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[136]  R. Furneaux,et al.  One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. , 1998, Biochemistry.

[137]  E. Sausville,et al.  Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. , 1998, Blood.

[138]  D. Roy,et al.  Conjugation of Blocked Ricin to an Anti-CD19 Monoclonal Antibody Increases Antibody-Induced Cell Calcium Mobilization and CD19 Internalization , 1997 .

[139]  R. Collins,et al.  A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. , 1996, Blood.

[140]  S. Zhao,et al.  The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. , 1996, Blood.

[141]  J. Sklar,et al.  Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles , 1996, The Journal of experimental medicine.

[142]  C. Sebban,et al.  Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. , 1996, Leukemia.

[143]  R. Perez-soler,et al.  Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[144]  M. Rosenblum,et al.  Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia , 1994 .

[145]  T. Dexter,et al.  Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. , 1993, Blood.

[146]  J. M. Riordan,et al.  Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. , 1992, Journal of medicinal chemistry.

[147]  R. W. Brockman,et al.  Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. , 1991, Cancer research.

[148]  M. Schell,et al.  A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  W. Plunkett,et al.  2-Fluoro-ATP: A toxic metabolite of 9-β-D-arabinosyl-2-fluoroadenine , 1983 .

[150]  E. Gelfand,et al.  Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. , 1983, Blood.

[151]  A. Ammann,et al.  NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITY , 1975, The Lancet.

[152]  Susan O'Brien,et al.  Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia , 2006, Cancer.

[153]  P. Hadwiger,et al.  Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. , 2005, Blood.

[154]  I. Bernstein,et al.  Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD 33 acute myeloid leukemia , 2005 .

[155]  H. Koeffler,et al.  Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. , 2005, Experimental hematology.

[156]  Ph.D Jackie Walling MBChB.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates , 2005, Investigational New Drugs.

[157]  M. Bernstein,et al.  Imatinib mesylate ( STI 571 ) for treatment of children with Philadelphia chromosome – positive leukemia : results from a Children ’ s Oncology Group phase 1 study , 2004 .

[158]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[159]  I. Schmidt-Wolf,et al.  Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. , 2004, Haematologica.

[160]  J. Raizer,et al.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. , 2002, Neuro-oncology.

[161]  P. Dent,et al.  Flavopiridol Potentiates STI 571-induced Mitochondrial Damage and Apoptosis in BCR-ABL-positive Human Leukemia Cells 1 , 2002 .

[162]  G. Daley,et al.  Overcoming STI 571 resistance with the farnesyl transferase inhibitor SCH 66336 , 2002 .

[163]  S. Grant,et al.  Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) , 2002, Leukemia.

[164]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[165]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[166]  B. Pollock,et al.  Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. , 2000, Blood.

[167]  G. Reaman,et al.  Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia. , 1999, Leukemia & lymphoma.

[168]  A. Delannoy,et al.  2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia , 1998, Annals of Hematology.

[169]  D. Roy,et al.  Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. , 1997, Blood.

[170]  E. Estey,et al.  Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. , 1996, Leukemia.

[171]  M. Bally,et al.  Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor Efficacy , 1995 .

[172]  M. Rosenblum,et al.  Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. , 1994, Blood.

[173]  A. Fauci,et al.  Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. , 1988, Blood.

[174]  M. Wick,et al.  Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins , 1988 .

[175]  R. Warrell,et al.  Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  E. Gelfand,et al.  Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. , 1983, Blood.

[177]  J. Burchenal,et al.  Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.

[178]  L. Goodman,et al.  SYNTHESIS OF 9-BETA-D-ARABINOFURANOSYLGUANINE. , 1964, Biochemistry.